581800-64-8

Basic information

• Product Name: Benzaldehyde, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-ethoxy-
• CAS NO: 581800-64-8
• Molecular Formula: C15H24O3Si
• Molecular Weight: 280.439
• Mol File: 581800-64-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-ethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-ethoxy-(581800-64-8)
• EPA Substance Registry System: Benzaldehyde, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-ethoxy-(581800-64-8)

Safety Data

• Hazardous Substances Data: 581800-64-8(Hazardous Substances Data)

Upstream product

• 121-32-4 4-hydroxy-3-ethoxybenzaldehyde 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 130713-00-7 4,4'-((1E,1'E)-(1,4-phenylene)bis(ethene-2,1-diyl))bis(2-ethoxyphenol) 
• 1443299-32-8 4,4'-((1E,3E,5E)-hexa-1,3,5-triene-1,6-diyl)bis(2-ethoxyphenol) 
• 1383713-72-1 (4-(tert-butyldimethylsilyloxy)-3-ethoxyphenyl)methyltriphenylphosphonium bromide 
• 1383713-71-0 (4-(bromomethyl)-2-ethoxyphenoxy)(tert-butyl)dimethylsilane 
• 1383713-70-9 (4-(tert-butyldimethylsilyioxy)-3-ethoxyphenyl)methanol 
• 1383713-37-8 2-ethoxy-4-(4-(4-hydroxyphenyl)-2-methylbut-1-enyl)phenol 
• 1383713-66-3 tert-butyl(2-ethoxy-4-(3-phenylprop-1-enyl)phenoxy)dimethylsilane 
• 1383713-12-9 2-ethoxy-4-(3-phenylprop-1-enyl)phenol 

Relevant articles and documents

Molecular docking studies of (1E,3E,5E )-1,6-bis(substituted phenyl)-hexa-1,3,5-triene and 1,4-bis(substituted trans-styryl)benzene analogs as novel tyrosinase inhibitors

We simulated the docking of the tertiary structure of mushroom tyrosinase with our compounds. From the structure-tyrosinase inhibitory activity relationship, it is notable that compounds 4, 8 and 11 showed similar or better activity rates than kojic acid which was used as a positive control. Compounds 17, 21, and 23 among benzene analogs that possess the same substituent showed significantly lower tyrosinase inhibitory effects. Therefore, we have confirmed that among the compounds showing better tyrosinase inhibitory effects than kojic acid, the compounds with triene analogs have better tyrosinase inhibitory effect than the compounds with benzene analogs. Docking simulation suggested the mechanism of compounds by several key residues which had possible hydrogen bonding interactions. The pharmacophore model underlined the features of active compounds, 4,4′-((1E,3E,5E )-hexa-1,3,5-triene-1,6-diyl)diphenol, 5,5′-((1E,3E,5E )-hexa-1,3,5-triene-1,6-diyl)bis(2-methoxy-phenol), and 5,5′-((1 E,3E,5E )-hexa-1,3,5-triene-1,6-diyl)dibenzene-1,3-diol among triene derivatives which had several hydrogen bond groups on both terminal rings. The soundness of the docking results and the agreement with the pharmacophores suggest that it can be conveniently exploited to design inhibitors with an improved affinity for tyrosinase.